US 9566295
GNAQ targeted dsRNA compositions and methods for inhibiting expression
granted A61KA61K31/713A61P
Quick answer
US patent 9566295 (GNAQ targeted dsRNA compositions and methods for inhibiting expression) held by Alnylam Pharmaceuticals, Inc. expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K31/713, A61P, A61P17/00, A61P35/00